

CIRM Funded Clinical Trials

A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia

| | |
|-------------------------------|-------------------------------|
| Disease Area: | Leukemia, Acute Myeloid (AML) |
| Investigator: | Mark Chao |
| Institution: | Forty Seven Inc. |
| CIRM Grant: | CLIN2-10144 (Closed) |
| Award Value: | \$0 |
| Trial Sponsor: | Forty Seven Inc. |
| Trial Stage: | Phase 1 |
| Trial Status: | Recruiting |
| Targeted Enrollment: | 287 |
| ClinicalTrials.gov ID: | NCT03248479 |



Mark Chao

Details:

Forty Seven Inc. is conducting a Phase 1b clinical trial for acute myeloid leukemia patients. Leukemia stem cells have a protein on their surface that enable them to evade being identified and destroyed by the patient's own immune system. This protein also helps these leukemia stem cells survive traditional therapies such as chemotherapy, enabling the cancer to lie dormant for a period before returning and causing the patient to relapse. The team is using a combination of a monoclonal antibody and the drug Azacitidine to make the leukemia stem cells vulnerable to being attacked and destroyed by the immune system.

Design:

Open label, non-randomized treatment trial.

Goal:

- 1) Complete a phase 1b trial to determine the optimal treatment dose.
- 2) Safety and efficacy in combination with azacitidine.

News about this clinical trial:

Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer

Contact Trial Sponsor